Cardiocor

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cardiocor

Quick Facts

Property Description
Active ingredient Bisoprolol fumarate
Form Oral film-coated tablet
Pharmacological class Beta-Adrenergic Receptor Antagonist (Beta-blocker)
Common use Supports the cardiovascular system by managing heart rate and blood pressure
Origin Synthetic compound
Regulatory Status Prescription-only medicine (Rx)

What Type of Medicine is Cardiocor (Bisoprolol)?

Cardiocor is the commercial designation for a prescription-only medication containing the synthetic compound Bisoprolol fumarate, which is formally classified as a Beta-Adrenergic Receptor Antagonist, commonly known as a beta-blocker. Bisoprolol is uniquely characterized by its high cardioselectivity, making it a highly selective beta1 blocker. This specific action means the medicine primarily targets receptors located in the heart muscle and is clinically recognized for its focused influence on core cardiac function.


Composition and Physical Form

Cardiocor is supplied for oral administration and is typically presented as a film-coated tablet—a distinguishing formulation for precise drug delivery. The active component is Bisoprolol fumarate, which is combined with standard excipients necessary to maintain the tablet's integrity and ensure stable absorption when taken by mouth. This medicine is consistently manufactured and established as a controlled pharmaceutical preparation in markets requiring prescription (Rx) status.


General Purpose and Mechanism Principles

The overarching purpose of Cardiocor is to reduce strain and regulate activity within the cardiovascular system. This goal is achieved through the drug’s core action of decreasing the impact of hormones like adrenaline on the heart. Bisoprolol is a potent, highly beta1-selective adrenoceptor blocking agent. This classification means the drug reduces the heart's workload by gently slowing the heart rate and decreasing the force of the heart muscle’s contraction. This action broadly serves to stabilize and support cardiac function in clinical scenarios requiring controlled rate and pressure management.

Regulatory References

  1. FDA DailyMed record

What side effects are possible with Cardiocor?

Possible Side Effects and Safety Information

This information is based strictly on documentation from government regulatory authorities and includes officially documented adverse reactions and safety restrictions. It excludes all dosing, administration, mechanism of action, and therapeutic uses.

Critical Safety Concerns and Restrictions

Amoxicillin is contraindicated in patients with a history of a serious hypersensitivity reaction (e.g., anaphylaxis, Stevens-Johnson syndrome) to any penicillin or other beta-lactam antibiotic. Treatment must be discontinued immediately if an allergic reaction occurs.

Serious Adverse Reactions

  • Anaphylaxis: Serious and potentially fatal allergic reactions requiring emergency intervention.
  • Severe Cutaneous Adverse Reactions (SCAR): Including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).
  • Clostridium difficile-Associated Diarrhea (CDAD): Can range from mild to fatal colitis and may occur up to two months after treatment ceases.
  • Hepatic Dysfunction: Hepatitis and cholestatic jaundice have been reported, which can be severe.

Frequency-Classified Adverse Reactions

The following are classified based on regulatory frequency bands (e.g., Very Common: 1/10; Very Rare: < 1/10,000):

Classification Examples of Reactions (System-Organ Class)
Very Common Diarrhea (Gastrointestinal)
Common Skin rash, Nausea (Skin; Gastrointestinal)
Uncommon Vomiting, Urticaria (Gastrointestinal; Skin)
Very Rare Agranulocytosis, Hepatitis, Interstitial nephritis, Convulsions (Blood; Hepato-biliary; Renal; Nervous System)

Population and Contextual Safety Notes

  • Infectious Mononucleosis: Amoxicillin should be avoided due to the high likelihood of a non-allergic rash.
  • Renal Impairment: Dose adjustment is required, as patients may be at a higher risk of convulsions.
  • Diagnostic Test Interference: May cause false-positive results in some urine glucose tests (copper reduction methods) and the Coombs test.
  • Exposure Patterns: Convulsions may occur with high doses. The overgrowth of non-susceptible organisms, such as candidiasis, may occur following prolonged use.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Cardiocor (Bisoprolol fumarate) is defined by official regulatory documents as a potentially life-threatening emergency requiring immediate medical intervention. The primary documented manifestations resulting from acute ingestion are severe bradycardia (abnormally slow heart rate) and pronounced hypotension (low blood pressure). These cardiovascular effects can progress rapidly to cardiogenic shock or acute heart failure. Other potential severe outcomes noted in regulatory guidance include seizures, coma, and possible bronchospasm.

Regulators mandate that any suspected overdose requires seeking immediate medical attention and contacting emergency services or a poison control center without delay. Treatment necessitates continuous hospital monitoring of vital signs and cardiac function, as there is no specific antidote known for Bisoprolol itself. Management is entirely supportive and symptomatic, focused on counteracting the severe cardiovascular depression.

Official guidance outlines that administration of established interventions for beta-blocker toxicity, such as Glucagon and sympathomimetic agents, may be required to manage these effects. Specific population risks include the potential for hypoglycemia (low blood sugar), which is noted as a particular concern in children. The official overdose profile emphasizes that the severe physiological effects necessitate specialized, controlled care.

Therapeutic Uses of Cardiocor

What Cardiocor Treats: Main Uses and Benefits

Cardiocor is generally utilized for the long-term therapeutic management of several cardiovascular conditions, providing support for cardiac function and reducing the symptomatic burden on the patient. This medicine is commonly used to help with high blood pressure (hypertension), additional symptomatic support for chronic heart failure (HFrEF), prophylaxis for stable angina pectoris, and assisting with managing heart rate and rhythm in certain tachyarrhythmias.

The medication is an established part of the long-term management plan for conditions marked by increased physiological stress. It helps address symptom clusters that may become intense or disruptive, such as exertional chest pain and noticeable palpitations, which interfere with daily comfort. The application of this medication is relevant for providing cardiovascular support and assists with long-term management. This usage is relevant when supportive symptom management is appropriate, assisting with functional stability and contributing to positive long-term outcomes.


Quick Fact

Quick Fact: Relief for Anginal Chest Discomfort. The medication provides supportive symptomatic relief, assisting with the long-term management of predictable chest pain associated with coronary artery disease.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Cardiocor?

Cardiocor (Bisoprolol) is approved for use in adults for its labeled cardiovascular indications. However, official regulatory documents define clear exclusions and restrictions for specific populations.

The medicine is contraindicated and must not be used in patients with acute or overt cardiac failure requiring intravenous therapy, cardiogenic shock, second or third-degree atrioventricular (AV) block (unless a pacemaker is present), or marked symptomatic sinus bradycardia. Additionally, use is prohibited in individuals with severe bronchial asthma, severe Chronic Obstructive Pulmonary Disease (COPD), metabolic acidosis, or known hypersensitivity to the drug.

For pediatric populations, use is not recommended as safety and efficacy have not been established in children and adolescents. Older adults are generally eligible, but increased caution is warranted.

Specific limitations apply to patients with severe renal or hepatic impairment, where dosage may be formally restricted. Furthermore, use requires caution in patients with diabetes mellitus due to the risk of masking hypoglycemia symptoms. During pregnancy and lactation, use is generally restricted and requires a clear medical need, as documented in regulatory guidelines.

What should I know about interactions with other medicines?

Cardiocor (bisoprolol fumarate) interacts with other medicines, primarily due to its effect on heart rate, blood pressure, and cardiac conduction. Certain combinations are generally not recommended due to the risk of serious side effects on the heart.

Combinations Not Recommended

  • Other beta-blockers: Combining with other agents of the same class should be avoided, as this may lead to an excessive reduction of sympathetic nervous system activity.
  • Calcium antagonists (Verapamil or Diltiazem type): Co-administration may result in an additive negative effect on the heart's contractility and electrical conduction, which can cause severe bradycardia (slow heart rate) or heart block. Intravenous Verapamil in particular carries a high risk of profound hypotension and AV block.
  • Centrally acting antihypertensive drugs (e.g., Clonidine, Methyldopa): Concomitant use can further slow the heart and potentially worsen heart failure. If Clonidine withdrawal is necessary, Cardiocor should be stopped several days prior to discontinuing Clonidine.

Combinations Requiring Caution and Monitoring

  • Antiarrhythmic drugs (Class I e.g., Flecainide; Class III e.g., Amiodarone): These combinations can potentiate the effects on AV conduction time and may increase the risk of an overly slow heartbeat.
  • Insulin and oral antidiabetic drugs: Cardiocor can increase the blood sugar-lowering effect and may mask the common warning signs of hypoglycemia, such as a rapid heartbeat.
  • Non-steroidal anti-inflammatory drugs (NSAIDs): These medicines may reduce the blood pressure-lowering effect of Cardiocor.

Mechanism of Action

How Cardiocor Works

Cardiocor (Bisoprolol) exerts its influence through the highly selective and competitive antagonism of beta1-adrenergic receptors . This action modulates two primary physiological systems influencing cardiac performance.

Selective Blockade of Cardiac beta1 Receptors

This core mechanistic domain involves the drug binding to beta1-adrenoceptors in the heart's muscle and electrical conduction system, suppressing the activating signals of epinephrine and norepinephrine. This molecular interference leads to the following physiological effects: negative chronotropy (a reduction in the heart rate) and negative inotropy (a reduction in the force of contraction), modulating the rate and force of cardiac performance, thereby reducing myocardial oxygen consumption.

Modulation of the Renal Hormonal Axis (RAS)

A complementary mechanism involves Cardiocor's action on beta1 receptors located in the kidney's juxtaglomerular cells. By blocking these renal receptors, the drug reduces the release of Renin, the enzyme that initiates the Renin-Angiotensin System (RAS) cascade. This action reduces the downstream production of vasoconstrictive hormones, influencing the level of systemic vascular tone.

Mechanism Constraint: Loss of Selectivity

The beta1-receptor selectivity of the antagonism is concentration-dependent. At significantly higher-than-therapeutic concentrations, the drug may lose this specificity and begin to block beta2-adrenoceptors found in non-cardiac tissues, altering the selectivity profile of the antagonism in non-cardiac tissues.

Dosage and Administration Information

How Cardiocor is Used

Cardiocor (Bisoprolol fumarate) is administered exclusively via the oral route as a film-coated tablet, following established procedural guidelines. The medicine is taken once daily, preferably in the morning, and intake is permitted with or without food as absorption is not clinically affected by meals.

Official Dosing and Administration Parameters

Established guidelines define distinct dosage ranges based on the condition being addressed.

Indication Starting Dose (Once Daily) Maximum Labeled Dose (Once Daily)
Hypertension & Stable Angina 5 mg (may start at 2.5 mg) 20 mg
Stable Chronic Heart Failure (CHF) 1.25 mg 10 mg

Procedural Usage Requirements

Treatment with Cardiocor is generally considered long-term, and the administration protocol includes specific procedural mandates. For Chronic Heart Failure management, the starting 1.25 mg dose is followed by a slow, gradual dose increase (titration) over several weeks until the target maintenance dose is reached. The tablets must be swallowed whole with liquid and should not be crushed or chewed, though some scored tablets can be divided for accurate dosing, such as the 1.25 mg initial dose for CHF.

Official instructions also mandate procedural caution upon stopping treatment. Abrupt withdrawal is strictly prohibited; the dosage must be reduced slowly over a period, typically one to two weeks, to prevent adverse physiological responses. Dose modifications are also necessary for specific populations, such as initiating a lower dose (2.5 mg once daily) and titrating slowly for patients with significant renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cardiocor

Evidence Studied in Chronic Heart Failure (HFrEF)

Cardiocor (Bisoprolol) was studied for chronic, stable heart failure with reduced ejection fraction (HFrEF). The research has involved multiple large-scale, placebo-controlled Randomized Controlled Trials (RCTs) conducted over long-term durations, typically 1 to 3 years. Researchers in these studies examined outcomes related to all-cause mortality and cardiovascular death, and the rate of hospitalization due to heart failure exacerbation. Studies also monitored functional measures, such as changes in Left Ventricular Ejection Fraction (LVEF) and patient functional status.

Multiple large RCTs reported measurements related to all-cause mortality and heart failure-related hospitalizations. Trials described changes in the incidence of sudden death and hospitalizations between the groups observed. However, the largest outcome trials generally excluded patients with acutely decompensated heart failure or those with very severe, unstable conditions. The existing evidence primarily examines the use of Cardiocor as an add-on to other foundational heart failure therapies, rather than as initial monotherapy.


Evidence Studied in High Blood Pressure (Hypertension)

Research examined the use of Cardiocor for high blood pressure (hypertension) across various clinical trial designs. The core outcomes monitored were simple, focusing on the change in Systolic and Diastolic Blood Pressure (BP), the reduction in Heart Rate (HR), and whether patients achieved specific target BP levels.

Research describes measurements related to systolic and diastolic blood pressure readings in the observed populations. Comparative research described patterns related to the blood pressure response rates. Direct evidence from long-term outcome RCTs for preventing major events like stroke often relies on pooling data from the entire beta-blocker class (meta-analyses), not solely Bisoprolol. Also, studies occasionally reported differing responses in central blood pressure measurements depending on the patient's position.


What Remains Uncertain in the Research

While a substantial body of evidence was observed for the core indications, several research limitation frames apply. Comparative evidence is lacking in large-scale, head-to-head outcome trials against every alternative medicine. Furthermore, specific findings were mixed or inconsistent across studies. Research provides context but not individual predictions, and the findings reflect the specific conditions under which they were conducted.

Key Studies & References

  1. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
  2. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina
  3. Bisoprolol - StatPearls - NCBI Bookshelf (Review of Indications and Guidelines)
  4. Label: BISOPROLOL FUMARATE tablet, film coated - DailyMed - NIH (Regulatory/Product Label Information)

Frequently Asked Questions (FAQ)

Common questions about Cardiocor (FAQ)


Q: What happens if I miss a dose of Cardiocor?

A: If a dose is missed, official product information advises taking it as soon as remembered. However, if it is almost time for your next scheduled dose, regulatory guidance suggests skipping the missed one. Taking two doses together is cautioned against, as this action may increase the risk of effects like a very slow heart rate or low blood pressure.

Q: Can Cardiocor cause fatigue or tiredness?

A: Yes, regulatory documents indicate that fatigue (feeling tired) and asthenia (a general lack of energy or weakness) are reported side effects in patients taking Cardiocor. These effects may sometimes be related to the amount of medicine taken.

Q: Is weight gain a potential side effect of Cardiocor?

A: Weight changes are a reported adverse effect associated with medicines in the beta-blocker class. It is important to know that sudden weight gain combined with swelling could be a sign of worsening heart failure, which should be immediately reported to a healthcare provider.

Q: Are there any signs of a serious side effect from Cardiocor I should watch for?

A: Regulatory advice includes being watchful for signs of worsening heart failure, which may include unusual shortness of breath, swelling in the ankles, feet, or legs, or sudden weight gain. Signs of excessively slow heart rate or low blood pressure, such as feeling dizzy or fainting, are signs that are officially recommended to be reported to a healthcare professional right away.

Q: Is it safe to drink alcohol while taking Cardiocor?

A: Official information indicates that alcohol may need to be consumed with caution while taking this medicine. Alcohol may have an additive effect with Cardiocor, meaning it could potentially lead to an excessive lowering of blood pressure, which may cause symptoms like dizziness or fainting.

Q: Does grapefruit juice affect how Cardiocor works?

A: Unlike some other cardiovascular medicines, official regulatory warnings regarding grapefruit juice are not consistently noted across all major regulatory labels for Cardiocor. This suggests that the interaction is not typically considered clinically significant for this specific product. Patients are generally advised to follow any specific dietary advice given by their healthcare team.

Q: Can Cardiocor be taken with vitamins or herbal supplements?

A: Official information does not list specific vitamins or herbal supplements as known interactions, but patients are officially advised to inform their doctor of all other medicines, vitamins, and supplements they are taking. The combination of any medicine with supplements is intended to be reviewed under the guidance of a healthcare professional.

Q: Can older adults safely take Cardiocor?

A: Cardiocor has been studied in older adults and response rates for managing high blood pressure were generally similar to those in younger patients. While dose adjustments based only on age are often not necessary, official information indicates that caution is warranted because older individuals may have age-related decreases in kidney function.

Q: What precautions should be taken when giving Cardiocor to children?

A: According to the official product information, the safety and effectiveness of Cardiocor have not been established in pediatric patients (children and adolescents). Therefore, this medicine is generally not recommended for use in this age group.

Q: Can women who are pregnant or breastfeeding use Cardiocor?

A: Official guidelines state that use during pregnancy is typically restricted due to the potential for risks to the fetus. It should only be used if the potential benefit clearly justifies the potential risk. For nursing mothers, it is unknown if the drug passes into human milk, and caution must be exercised by the prescriber.

Q: Can Cardiocor affect kidney function?

A: Cardiocor is eliminated from the body by both the kidneys and the liver. Patients with severe renal impairment (poor kidney function) may require a lower starting dose or a slower increase in dosage because the body may clear the drug less quickly.

Q: Is dizziness common when first starting Cardiocor?

A: Dizziness is a commonly reported adverse reaction in clinical trials, especially when starting treatment or after a dose increase. This can be a symptom of low blood pressure or an excessively slow heart rate. Following the specific instructions on taking the medicine is recommended to minimize risk.

Q: Is Cardiocor generally safe for people with diabetes?

A: Cardiocor must be used with caution in patients with diabetes mellitus. Official warnings note that beta-blockers may mask certain physical signs of acute hypoglycemia (low blood sugar), specifically a rapid heart rate (tachycardia). It is generally recommended that patients with diabetes monitor their blood sugar levels closely.

Q: What lifestyle changes are recommended while on Cardiocor?

A: Official information outlines general precautions to consider while adjusting to the medicine. Precautions described include minimizing sudden movements, such as quickly changing position (sitting up or standing), and exercising caution when driving or operating machinery until the effects of the medicine are known. Alcohol intake should be minimized.

Q: Is it normal for my heart rate to slow down after starting Cardiocor?

A: Yes, one of the key ways Cardiocor works is by producing a negative chronotropic effect, which means it slows the heart rate. Bradycardia (an abnormally slow heart rate) is a commonly reported side effect, and the heart rate is monitored by your doctor, especially when treatment begins.

Q: Why do some people experience cold hands and feet on Cardiocor?

A: The official product information lists coldness or numbness in the extremities (hands and feet) as a common side effect. This is likely due to the drug’s influence on circulation in the blood vessels near the skin's surface.

Q: How long does Cardiocor stay in your system?

A: Official pharmacological data indicates that the elimination half-life of the drug is approximately 9 to 12 hours. The body typically takes about 5 days of once-daily dosing for the amount of medicine in the blood to reach a stable, consistent level.

Q: Does Cardiocor cause sleep disturbances or insomnia?

A: Yes, insomnia (difficulty sleeping) is reported as a commonly observed side effect. Additionally, sleep disorders and nightmares are also listed in regulatory documents as uncommon adverse effects.

Q: Can Cardiocor affect mood or cause depression?

A: Regulatory documents report that depression is listed as an uncommon side effect. Other central nervous system effects, such as anxiety and confusion, have also been reported with the use of this medicine.

Q: What should I tell my dentist before a procedure if I'm taking Cardiocor?

A: If you are scheduled for surgery or a dental procedure that requires general anesthesia, regulatory guidance suggests informing the medical team that Cardiocor is being taken. The anesthesiologist needs to know about the beta-blockade due to potential interactions with other anesthetic drugs that could excessively slow your heart rate.

Q: Is it normal to feel a tingling sensation when taking Cardiocor?

A: A condition known as paresthesia, which can include a tingling or numbness sensation, is listed as an uncommon side effect of this medicine in the official documentation.

Q: Does taking Cardiocor at night or in the morning make a difference?

A: Official instructions generally recommend taking the medicine once daily in the morning. While regulatory labels specify this preferred timing, they typically do not detail the clinical differences between morning and evening dosing for all patients.

How should Cardiocor be stored and disposed of?

How to Store and Dispose of Cardiocor

This information reflects the mandatory storage and disposal requirements for Cardiocor as documented in official government regulatory labeling.

Official Storage Requirements

Requirement Type Regulatory Statement
Temperature Store below 25 C or 30 C (depending on the product).
Protection Store in the original package to protect from light.
Child Safety Keep this medicine out of the sight and reach of children.
Stability Some packaging types may have a defined in-use shelf life after first opening (e.g., 6 months).

Disposal Instructions

All unused or expired Cardiocor, including any waste material, must be disposed of in accordance with local requirements for pharmaceutical waste. Do not dispose of this medicine in household trash or wastewater unless specifically instructed by a healthcare provider or pharmacist.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cardiocor found in:

A-Z Index: